Literature DB >> 8193417

Chronic hemodialysis patients. Part II: Reducing drug-related problems through application of the focused drug therapy review program.

B Kaplan1, L A Shimp, N A Mason, F J Ascione.   

Abstract

OBJECTIVE: To test the value and measure the impact of a model of pharmacy practice called the Focused Drug Therapy Review Program (FDTRP) in patients with endstage renal disease on hemodialysis.
DESIGN: A modified version of FDTRP, adapted for a hemodialysis population, was assessed for its impact on prescriber behavior. The impact was measured by examining the percentage of pharmacist therapeutic recommendations accepted and implemented by the prescriber.
SETTING: Thirty patients at a university hospital-based outpatient hemodialysis unit participated in the study. Twenty-four patients completed the study through the implementation evaluation.
RESULTS: The pharmacist generated 114 therapeutic recommendations and 85 informative comments regarding drug therapy. The prescriber accepted 76 percent and implemented 70 percent of the therapeutic recommendations. The prescriber considered the informative comments to be helpful, even if the information was known previously.
CONCLUSIONS: The FDTRP has been shown to be useful in the care of chronic hemodialysis patients. In addition, the pharmacist was able to provide clinically important recommendations in a closely monitored patient population.

Entities:  

Mesh:

Year:  1994        PMID: 8193417     DOI: 10.1177/106002809402800304

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  11 in total

1.  Medication reconciliation and therapy management in dialysis-dependent patients: need for a systematic approach.

Authors:  Amy Barton Pai; Katie E Cardone; Harold J Manley; Wendy L St Peter; Rachel Shaffer; Michael Somers; Rajnish Mehrotra
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 8.237

2.  Effects of chronic kidney disease on liver transport: quantitative intravital microscopy of fluorescein transport in the rat liver.

Authors:  Jennifer C Ryan; Kenneth W Dunn; Brian S Decker
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-10-22       Impact factor: 3.619

Review 3.  Drug-related problem in children with chronic kidney disease.

Authors:  Norkasihan Ibrahim; Ian Ck Wong; Susan Patey; Stephen Tomlin; Manish D Sinha; Yogini Jani
Journal:  Pediatr Nephrol       Date:  2012-03-28       Impact factor: 3.714

4.  Detection of prescription errors by a unit-based clinical pharmacist in a nephrology ward.

Authors:  Ghazal Vessal
Journal:  Pharm World Sci       Date:  2009-10-17

5.  Implementation of clinical pharmacy services in a pediatric dialysis unit.

Authors:  Radwa El Borolossy; Lamia El Wakeel; Ihab El Hakim; Osama Badary
Journal:  Pediatr Nephrol       Date:  2014-02-16       Impact factor: 3.714

6.  Ambulatory Medication Reconciliation in Dialysis Patients: Benefits and Community Practitioners' Perspectives.

Authors:  Jo-Anne S Wilson; Matthew A Ladda; Jaclyn Tran; Marsha Wood; Penelope Poyah; Steven Soroka; Glenn Rodrigues; Karthik Tennankore
Journal:  Can J Hosp Pharm       Date:  2017-12-21

Review 7.  Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: a systematic literature review.

Authors:  Gunar Stemer; Rosa Lemmens-Gruber
Journal:  BMC Nephrol       Date:  2011-07-22       Impact factor: 2.388

8.  A pharmacy-based medication reconciliation and review program in hemodialysis patients: a prospective study.

Authors:  Nicholas J Patricia; Edward F Foote
Journal:  Pharm Pract (Granada)       Date:  2016-09-15

9.  Medication-related problem type and appearance rate in ambulatory hemodialysis patients.

Authors:  Harold J Manley; Debra K Drayer; Richard S Muther
Journal:  BMC Nephrol       Date:  2003-12-22       Impact factor: 2.388

Review 10.  Understanding the implementation of interventions to improve the management of chronic kidney disease in primary care: a rapid realist review.

Authors:  Jung Yin Tsang; Tom Blakeman; Janet Hegarty; John Humphreys; Gill Harvey
Journal:  Implement Sci       Date:  2016-04-04       Impact factor: 7.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.